1. Home
  2. CLST vs LUNG Comparison

CLST vs LUNG Comparison

Compare CLST & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Catalyst Bancorp Inc.

CLST

Catalyst Bancorp Inc.

HOLD

Current Price

$15.87

Market Cap

66.9M

Sector

N/A

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.28

Market Cap

57.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLST
LUNG
Founded
1922
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.9M
57.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
CLST
LUNG
Price
$15.87
$1.28
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$5.38
AVG Volume (30 Days)
5.4K
538.0K
Earning Date
04-30-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
171.79
7.64
EPS
0.56
N/A
Revenue
N/A
$90,497,000.00
Revenue This Year
N/A
$2.48
Revenue Next Year
N/A
$18.46
P/E Ratio
$28.34
N/A
Revenue Growth
N/A
8.01
52 Week Low
$11.62
$1.13
52 Week High
$18.16
$3.88

Technical Indicators

Market Signals
Indicator
CLST
LUNG
Relative Strength Index (RSI) 41.58 45.70
Support Level $15.20 $1.19
Resistance Level $15.97 $1.45
Average True Range (ATR) 0.08 0.09
MACD 0.00 0.01
Stochastic Oscillator 5.00 37.04

Price Performance

Historical Comparison
CLST
LUNG

About CLST Catalyst Bancorp Inc.

Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: